A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer [MARIPOSA].
- Richardson, Gary (Primary Chief Investigator (PCI))
- Lai, Li Hoon (Project Manager)
Project: Research